This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, J. Articles by Maeda, H. Search for Related Content PubMed PubMed Citation Articles by Wu, J. Articles by Maeda, H.

Modulation of Enhanced Vascular Permeability in Tumors by a Bradykinin Antagonist, a Cyclooxygenase Inhibitor, and a Nitric Oxide Scavenger¹

Department of Microbiology, Kumamoto University School of Medicine, Kumamoto 860, Japan

The mechanism of the enhanced vascular permeability and retention (EPR) effect seen in solid tumors was investigated with sarcoma 180 (S-180) in mice by using the bradykinin receptor antagonist D-Arg-[Hyp³,Thi⁵,D-Tic⁷,Oic⁸]bradykinin] (HOE 140), the nitric oxide (NO) scavenger 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO), and the cyclooxygenase (prostaglandin synthase) inhibitor indomethacin. In the S-180 solid tumor model, administration of HOE 140 (0.65 or 1.3 µg/kg/8 h, s.c.), PTIO (167 mg/kg/2 h, four times/8 h, i.p.), or indomethacin (5 or 10 mg/kg/day, three times, i.p.) significantly suppressed the EPR effect in the tumor, and the combined administration of these agents achieved a stronger inhibition of the EPR effect than did each compound alone. Indomethacin (10 mg/kg/day, three times) plus PTIO (167 mg/kg/2 h, four times) given i.p. had the greatest inhibition (70%) on the EPR effect. When HOE 140 was administered s.c. at a dose of 13 µg/kg/12 h for 2 weeks after tumor inoculation, growth of the solid tumor was also suppressed by 32%, by tumor weight. In the ascitic form of S-180, i.p. administration of HOE 140 at 13 µg/kg/12 h initiated immediately after tumor inoculation significantly suppressed formation of S-180 tumor ascites; the life span of ascitic S-180 tumor-bearing mice was prolonged at the same dose of HOE 140. The expression of inducible NO synthase mRNA and of cyclooxygenase 2 mRNA in S-180 tumor tissue was highly elevated, as evidenced by Northern blotting and reverse transcription-PCR and by Southern blot analyses. These results indicate that bradykinin, NO, and prostaglandins play an important role in enhanced vascular permeability in tumor tissue and sustain tumor growth. More importantly, bradykinin antagonists such as HOE 140 may be beneficial for the inhibition of tumor growth.

¹ This work was supported by Grant-in-Aid 06282247 for Research on Cancer from the Ministry of Education, Culture, Sports and Science of Japan (Monbusho). J. W. is a grantee of a Japanese Government (Monbusho) Scholarship.

² To whom requests for reprints should be addressed, at Department of Microbiology, Kumamoto University School of Medicine, 2-2-1 Honjo, Kumamoto 860, Japan. Phone: 81-96-373-5098; Fax: 81-96-362-8362; E-mail: msmaedah@gpo.kumamoto-u.ac.jp.

Received 7/17/97. Accepted 10/30/97.

This article has been cited by other articles:

				A. Nagamitsu, K. Greish, and H. Maeda Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors Jpn. J. Clin. Oncol., November 1, 2009; 39(11): 756 - 766. [Abstract] [Full Text] [PDF]

				C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF]

				P. O. Berberat, Z. Dambrauskas, A. Gulbinas, T. Giese, N. Giese, B. Kunzli, F. Autschbach, S. Meuer, M. W. Buchler, and H. Friess Inhibition of Heme Oxygenase-1 Increases Responsiveness of Pancreatic Cancer Cells to Anticancer Treatment Clin. Cancer Res., May 15, 2005; 11(10): 3790 - 3798. [Abstract] [Full Text] [PDF]

				O. Soepenberg, M. J. A. de Jonge, A. Sparreboom, P. de Bruin, F. A. L. M. Eskens, G. de Heus, J. Wanders, P. Cheverton, M. P. Ducharme, and J. Verweij Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors Clin. Cancer Res., January 15, 2005; 11(2): 703 - 711. [Abstract] [Full Text] [PDF]

				Y. Ikeda, I. Hayashi, E. Kamoshita, A. Yamazaki, H. Endo, K. Ishihara, S. Yamashina, Y. Tsutsumi, H. Matsubara, and M. Majima Host Stromal Bradykinin B2 Receptor Signaling Facilitates Tumor-Associated Angiogenesis and Tumor Growth Cancer Res., August 1, 2004; 64(15): 5178 - 5185. [Abstract] [Full Text] [PDF]

				N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, and K. Kataoka Novel Cisplatin-Incorporated Polymeric Micelles Can Eradicate Solid Tumors in Mice Cancer Res., December 15, 2003; 63(24): 8977 - 8983. [Abstract] [Full Text] [PDF]

				J. Fang, T. Sawa, T. Akaike, T. Akuta, S. K. Sahoo, G. Khaled, A. Hamada, and H. Maeda In Vivo Antitumor Activity of Pegylated Zinc Protoporphyrin: Targeted Inhibition of Heme Oxygenase in Solid Tumor Cancer Res., July 1, 2003; 63(13): 3567 - 3574. [Abstract] [Full Text] [PDF]

				W. C. Wolf, D. M. Evans, L. Chao, and J. Chao A Synthetic Tissue Kallikrein Inhibitor Suppresses Cancer Cell Invasiveness Am. J. Pathol., November 1, 2001; 159(5): 1797 - 1805. [Abstract] [Full Text] [PDF]

				C. Li, S. Ke, Q.-P. Wu, W. Tansey, N. Hunter, L. M. Buchmiller, L. Milas, C. Charnsangavej, and S. Wallace Tumor Irradiation Enhances the Tumor-specific Distribution of Poly(L-glutamic acid)-conjugated Paclitaxel and Its Antitumor Efficacy Clin. Cancer Res., July 1, 2000; 6(7): 2829 - 2834. [Abstract] [Full Text]

				T. Sawa, J. Wu, T. Akaike, and H. Maeda Tumor-targeting Chemotherapy by a Xanthine Oxidase-Polymer Conjugate That Generates Oxygen-free Radicals in Tumor Tissue Cancer Res., February 1, 2000; 60(3): 666 - 671. [Abstract] [Full Text]

				S. Mori, K. Murakami-Mori, S. Nakamura, A. Ashkenazi, and B. Bonavida Sensitization of AIDS-Kaposi's Sarcoma Cells to Apo-2 Ligand-Induced Apoptosis by Actinomycin D J. Immunol., May 1, 1999; 162(9): 5616 - 5623. [Abstract] [Full Text] [PDF]